Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer
Anti-Cancer Drugs, Volume 17, No. 3, Year 2006
Notification
URL copied to clipboard!
Description
A phase II study was conducted to evaluate the safety and efficacy of an oxaliplatin (OXA)/vinorelbine (VNB) combination in metastatic breast cancer (MBC) patients pre-treated with anthracyclines and taxanes. Patients received OXA at 130 mg/m2 (2-h i.V.), day 1, and VNB days 1 and 8 at 24-26 mg/m2 repeated every 3 weeks. Forty-two patients (median age 54; 64% with liver metastasis, 67% taxane resistant/refractory and 38% anthracycline resistant/refractory) were treated. A median of 4 cycles of treatment was given per patient, with 31% receiving 6 or more. Eleven partial responses and 16 patients with stable disease (five lasting more than 4 months) in 41 eligible patients were seen, for an overall response rate of 26.8% (95% confidence interval 14.2-42.9). Median follow-up was 15.9 months (7.2-30.6), median time to progression was 3.4 months and estimated overall survival was 12.7 months (20 events). Thirty-three patients experienced (National Cancer Institute Common Toxicity Criteria version 2) grade 3-4 neutropenia (one case of febrile neutropenia) and three patients had severe constipation requiring hospitalization. Nine patients developed grade 3 OXA-specific neurotoxicity. There were no treatment-related deaths. We conclude that OXA 130 mg/m2 (day 1) and VNB 24 mg/m2 (day 1 and 8) combination given every 3 weeks is effective with a good safety profile in MBC patients previously treated with anthracyclines and taxanes. © 2006 Lippincott Williams & Wilkins.
Authors & Co-Authors
Petit, Thierry
France, Strasbourg
Centre Paul Strauss Centre Régional de Lutte Contre le Cancer de Strasbourg
Benider, Abdellatif
Morocco, Casablanca
Chu Averroes
Yovine, Alejandro
France, Le Kremlin-bicetre
Cac
Bougnoux, Philippe
France, Tours
Hopital Bretonneau
Spaeth, Dominique
France, Vandoeouvre-les-nancy
Centre Alexis Vautrin
Maindrault-Goebel, Frédérique
France, Paris
Hôpital Saint-antoine
Serin, Daniel
France, Avignon
Institut Sainte Catherine
Tigaud, Jean Dominique
France, Lyon
Hopital Edouard Herriot
Eymard, Jean Christophe
France, Reims
Institut Jean-godinot
Simon, Hélène
France, Brest
Centre Hospitalier Universitaire de Brest
Bertaux, Brigitte
Unknown Affiliation
Brienza, Silvano
Unknown Affiliation
Cvitkovic, Esteban
France, Le Kremlin-bicetre
Cac
Statistics
Citations: 22
Authors: 13
Affiliations: 10
Identifiers
Doi:
10.1097/00001813-200603000-00013
ISSN:
09594973
Research Areas
Cancer
Health System And Policy
Study Design
Cohort Study